ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,237.79
0.45%
Dow Jones
39,558.91
0.43%
US Dollar vs MXN
16.75081
-0.26%
Brent Oil
83.965
0.02%
Bitcoin
63,000.00
-0.08%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. AgeX Therapeutics Inc (AGE)

  7. AgeX Therapeutics Inc (AGE) Noticias

AGE

AgeX Therapeutics (AGE)

AgeX Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:AGE
FechaHoraFuenteTítuloSímboloCompañía
22/03/202416:27GlobeNewswire Inc.AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
07/03/202415:49Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsAMEX:AGEAgeX Therapeutics Inc
07/03/202415:47Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
07/03/202406:47Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
13/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:AGEAgeX Therapeutics Inc
18/01/202416:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:AGEAgeX Therapeutics Inc
16/01/202408:11Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]AMEX:AGEAgeX Therapeutics Inc
15/11/202308:38Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:AGEAgeX Therapeutics Inc
14/11/202315:05Business WireAgeX Therapeutics Reports Third Quarter 2023 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
07/11/202315:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:AGEAgeX Therapeutics Inc
22/09/202315:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:AGEAgeX Therapeutics Inc
30/08/202306:00Business WireSerina Therapeutics and AgeX Therapeutics Enter into Merger AgreementAMEX:AGEAgeX Therapeutics Inc
14/08/202315:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:AGEAgeX Therapeutics Inc
14/08/202315:05Business WireAgeX Therapeutics Reports Second Quarter 2023 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
24/07/202317:28Business WireAgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred StockAMEX:AGEAgeX Therapeutics Inc
21/07/202316:32Business WireAgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred StockAMEX:AGEAgeX Therapeutics Inc
08/06/202315:06Edgar (US Regulatory)Current Report Filing (8-k)AMEX:AGEAgeX Therapeutics Inc
23/05/202315:05Business WireAgeX Therapeutics Announces Appeal of NYSE American DeterminationAMEX:AGEAgeX Therapeutics Inc
18/05/202315:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:AGEAgeX Therapeutics Inc
12/05/202315:05Business WireAgeX Therapeutics Reports First Quarter 2023 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
26/04/202315:05Business WireAgeX Therapeutics Receives Stock Exchange Deficiency LetterAMEX:AGEAgeX Therapeutics Inc
31/03/202315:05Business WireAgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
22/03/202315:20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:AGEAgeX Therapeutics Inc
22/03/202315:17Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)AMEX:AGEAgeX Therapeutics Inc
06/02/202315:07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)AMEX:AGEAgeX Therapeutics Inc
25/11/202214:41Business WireAgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsAMEX:AGEAgeX Therapeutics Inc
10/11/202215:21Edgar (US Regulatory)Quarterly Report (10-q)AMEX:AGEAgeX Therapeutics Inc
10/11/202215:05Business WireAgeX Therapeutics Reports Third Quarter 2022 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
02/11/202215:48Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)AMEX:AGEAgeX Therapeutics Inc
05/10/202215:07Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)AMEX:AGEAgeX Therapeutics Inc
 Showing the most relevant articles for your search:AMEX:AGE

Su Consulta Reciente

USOTC
RHHBY
Roche (QX)
USOTC
ADDYY
Adidas (QX)
NYSE
CVX
Chevron
AMEX
XLE
Energy Select Sector SPDR
NYSE
XOM
Exxon Mobil
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
NVDA
NVIDIA
FX
EURUSD
Euro vs US Dollar
NYSE
MCD
McDonalds
NYSE
BAC
Bank of America
CCOM
OILBRENT
Brent Oil
NYSE
DIS
Walt Disney
USI
USTECH100
US Tech 100
CCOM
US30
US 30
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados